CVS stock forecast, quote, news & analysis

Key Takeaways

• CVS Health shares traded near $94.71 as of mid-October 2026, up roughly 6.6% over the trailing 30 days after rebounding from a late-September trough near $85.
• Over the trailing three months, the stock is still down about 12%, reflecting a sharp early-August pullback that followed its second-quarter earnings release.
• Q2 2026 results showed adjusted EPS of $2.58, up more than 40% year over year, alongside an improved medical benefit ratio of 87.4% and a raised full-year outlook.
• Management lifted 2026 adjusted EPS guidance to $7.90–$8.10 and indicated an "at least $8.44" adjusted EPS floor for 2027.
• CMS 2027 Star Ratings released in early October showed lower Aetna 4+ star membership, a headwind analysts expect to weigh on 2028 quality bonus payments.

Current Market Snapshot

CVS Health (NYSE: CVS) has recovered ground through mid-October, climbing from a September low near $85 to roughly $94.71 in recent sessions. The move was supported in part by a broader defensive rotation, as hotter inflation data prompted investors to shift capital out of richly valued technology and chip names and toward healthcare and consumer staples. The stock still trades well below its mid-July peak near $110, leaving shares at a forward price-to-earnings multiple of roughly 11, a discount to the broader medical services group. The company also pays a quarterly dividend of $0.665 per share, representing an annualized yield of about 2.9%.

CVS Health (CVS) Business Overview and Competitive Position

CVS Health is a diversified health solutions company headquartered in Woonsocket, Rhode Island, operating across three main segments. Its Health Care Benefits segment, anchored by Aetna, administers commercial, Medicare Advantage, and Medicaid health plans. The Health Services segment is built around Caremark, one of the largest pharmacy benefit managers in the United States, along with care-delivery assets such as Oak Street Health and Signify Health. The Pharmacy & Consumer Wellness segment spans roughly 9,000 retail pharmacy locations and MinuteClinic. This integrated model gives CVS scale across prescription flow, drug pricing, and care delivery, positioning the stock as a defensive, value-oriented healthcare holding that competes with large managed-care groups such as UnitedHealth (UNH) and Humana (HUM).

Recent Developments Driving CVS

CVS reported second-quarter 2026 results on August 5, posting revenue of $106.1 billion, up 7.3% year over year, and adjusted EPS of $2.58, well above the roughly $1.85–$1.87 consensus. Aetna's medical benefit ratio improved to 87.4% from 89.9% a year earlier, reflecting disciplined pricing and stronger Medicare cost control. Management raised full-year 2026 adjusted EPS guidance to $7.90–$8.10 from $7.30–$7.50, lifted revenue guidance to at least $414 billion, and increased operating cash flow guidance to at least $11.5 billion. Despite the beat, shares declined sharply in the following sessions as executives flagged 340B business pressures and expected membership declines at Caremark in 2027.

In early October, the Centers for Medicare & Medicaid Services published 2027 Star Ratings showing that more than 69% of Aetna's Medicare Advantage members are in 4+ star plans, down from more than 81% for 2026. Analysts at TD Cowen estimated an unmitigated headwind of about $720 million to 2028 earnings. Separately, CVS has expanded its GLP-1 strategy, participating in the CMS Medicare GLP-1 Bridge program and broadening weight-management offerings, including a collaboration with Eli Lilly (LLY) on Zepbound. Wall Street sentiment remains broadly constructive, with a consensus "Moderate Buy" rating and an average price target near $107.80.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots from a broader universe of hundreds of bots that trade thousands of tickers. Only the top-performing and most relevant robots are featured in this section, with each bot differing in strategy, timeframe, and performance metrics. This makes it a useful starting point for traders looking to compare systematic, data-driven approaches to market timing and signal generation. To explore the currently featured strategies and performance data, visit the Trending AI Robots page.

2026 Outlook and What Investors Should Watch

Looking ahead, CVS Health's third-quarter 2026 earnings, scheduled for November 4, represent the next major catalyst, with consensus expectations around $1.62 in adjusted EPS on revenue near $105 billion. Investors will monitor whether Aetna's medical cost ratio remains below management's full-year target near 89.75%, and whether the company sustains its raised guidance. Key themes for the remainder of 2026 and into 2027 include Medicare Advantage repricing, the 340B drug-pricing environment, ongoing PBM reform and regulatory scrutiny, Caremark membership trends, and the rollout of GLP-1 support programs. Star ratings, cash-flow durability, and debt-reduction progress will also shape how the market values the stock. These factors are informational in nature and are not intended as investment recommendations.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations